{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T23:11:14Z","timestamp":1778713874596,"version":"3.51.4"},"reference-count":38,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2004,9,16]],"date-time":"2004-09-16T00:00:00Z","timestamp":1095292800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2005,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>Previous research has suggested an association between use of atypical antipsychotics and onset of diabetes mellitus. We sought to compare the incidence of new onset diabetes among patients receiving atypical antipsychotics, traditional antipsychotics or antidepressants.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Retrospective cohort study of outpatients with claims for atypical antipsychotics (<jats:italic>n<\/jats:italic>\u2009=\u200910\u2009265) compared to controls with claims for traditional antipsychotics (<jats:italic>n<\/jats:italic>\u2009=\u20094607), antidepressants (<jats:italic>n<\/jats:italic>\u2009=\u200960\u2009856) or antibiotics (<jats:italic>n<\/jats:italic>\u2009=\u200959\u2009878) in the administrative claims database of a large pharmaceutical benefit manager between June 2000 and May 2002. Main outcome measures were adjusted and unadjusted incidence rates of diabetes (new cases per 1000 per year) in a 12\u2010month period, as measured using new prescriptions for antidiabetic drugs after a 6\u2010month lead\u2010in period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Annual unadjusted incidence rates of diabetes (new cases per 1000 per year) were 7.5 for atypical antipsychotics, 11.3 for traditional antipsychotics, 7.8 for antidepressants and 5.1 for antibiotics. In multivariable analyses, age, male sex and Chronic Disease Score were associated with greater odds of diabetes onset. There were no statistically significant differences in outcome between the atypical antipsychotic, traditional antipsychotic and antidepressant groups. Multivariable comparisons among specific agents showed increased odds of diabetes for clozapine, olanzapine, ziprasidone and thioridazine (relative to risperidone), but these comparisons did not reach statistical significance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In a large prescription claims database, outpatients taking atypical antipsychotics did not have higher rates of diabetes onset, compared to subjects taking traditional antipsychotics or antidepressants. Copyright \u00a9 2004 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.1016","type":"journal-article","created":{"date-parts":[[2004,9,16]],"date-time":"2004-09-16T10:00:35Z","timestamp":1095328835000},"page":"407-415","source":"Crossref","is-referenced-by-count":27,"title":["Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: a retrospective cohort study"],"prefix":"10.1002","volume":"14","author":[{"given":"Truls","family":"\u00d8stbye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lesley H.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leah E.","family":"Masselink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Hutchison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter E.","family":"Dans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin A.","family":"Schulman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranga R.","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,9,16]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3956(01)00020-6"},{"key":"e_1_2_1_3_2","unstructured":"The National Institute for Health Care Management Research and Educational Foundation.Prescription Drug Expenditures in 2001: Another Year of Escalating Costs. NICHM Foundation;2002. Available at:http:\/\/www.nihcm.org\/spending2001.pdf. [Accessed 8 October 2003]."},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(98)00105-4"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v62n0204"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.156.11.1686"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(01)01000-2"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(98)00100-0"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v59n0604"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.151.9.1395a"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.19327"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.psy.41.4.369"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.157.6.975"},{"key":"e_1_2_1_14_2","first-page":"187","article-title":"Diabetic ketoacidosis with clozapine treatment","volume":"12","author":"Maule S","year":"1999","journal-title":"Diabet Nutr Metab"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v60n0809f"},{"key":"e_1_2_1_16_2","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1176\/ajp.156.9.1471","article-title":"Olanzapine\u2010induced ketoacidosis with diabetes mellitus","volume":"156","author":"Lindenmayer JP","year":"1999","journal-title":"Am J Psychiatry"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0033-3182(99)71210-7"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v60n0809f"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v59n0604"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v58n0304"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.19327"},{"key":"e_1_2_1_22_2","first-page":"668","article-title":"New\u2010onset diabetes mellitus associated with quetiapine","volume":"45","author":"Procyshyn RM","year":"2000","journal-title":"Can J Psychiatry"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-5491.2000.00296.x"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.58.12.1172"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n1010"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.325.7358.243"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(02)00588-7"},{"key":"e_1_2_1_28_2","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1001\/jama.286.20.2542","article-title":"Atypical antipsychotic drugs and hyperglycemia in adolescents","volume":"286","author":"Koller E","year":"2001","journal-title":"JAMA"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(92)90016-G"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199508000-00004"},{"key":"e_1_2_1_31_2","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/01.MLR.0000053023.49899.3E","article-title":"Can pharmacy data improve prediction of hospital outcomes? Comparisons with a diagnosis\u2010based comorbidity measure","volume":"41","author":"Parker JP","year":"2003","journal-title":"Med Care"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(02)01646-6"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n1208"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200206000-00002"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.59.4.337"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(94)00234-H"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1300\/J055v05n01_02"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/154.9.854"},{"key":"e_1_2_1_39_2","volume-title":"National Center for Chronic Disease Prevention and Health Promotion. Diabetes Public Health Resource\u2014Statistics: 1999 Surveillance Report","author":"Centers for Disease Control and Prevention","year":"1999"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.1016","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.1016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T01:49:54Z","timestamp":1700185794000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.1016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9,16]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["10.1002\/pds.1016"],"URL":"https:\/\/doi.org\/10.1002\/pds.1016","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,9,16]]}}}